

UNMC T32 Training Program in Alzheimer's Disease and Related Dementia Drug Discovery (ADRD³) 2026-2027 Call for Student Scholarship Applications

About ADRD³: The UNMC Training Program in Alzheimer's Disease and Related Dementia Drug Discovery is a NIH funded T32 program administered jointly by the Department of Pharmaceutical Sciences and the Department of Neurological Sciences at UNMC. The training program is inspired by the need to develop a critical workforce of specialists in neurodegenerative diseases focusing on Alzheimer's Disease (AD) and drug development. Students will obtain a depth of knowledge within pharmacokinetic studies in experimental therapeutics and the drug development process. This program will improve the students' abilities to collaborate effectively on interdisciplinary teams with broad expertise to address challenges within target-based drug discovery concerning AD and related dementias.

Trainees will take defined courses in biochemistry, statistical analysis, pharmaceutical chemistry, neuroscience, responsible conduct of research, research design and scientific thinking, and the drug discovery process to provide a common skill set and language for interdisciplinary research. Workshops, seminars, and practical education will create essential skills for developing proficient personnel within the biomedical research community.

Eligibility:

- 1) Candidates should be working on a current AD or related dementia drug discovery project (broadly defined) or be able to propose such a project with their mentor's approval and willingness to support such a project.
- 2) Candidates should be Ph.D. graduate students in good standing.
- 3) Preference will be given to students who have passed their comprehensive exam and advanced to candidacy.
- 4) Candidates must be citizens or non-citizen nationals of the United States of America or have been lawfully admitted for permanent residence (in possession of a valid Alien Registration Receipt Card, or 'green card') at the time of the appointment.
- 5) Mentor must be existing T32 program faculty or commit to joining.

Application instructions: Please combine the following into a single pdf and send by email to Renee Kaszynski (renee.kaszynski@unmc.edu).

- 1) Personal statement outlining your interest in this T32 training program.
- 2) A NIH-style Specific Aims page of your AD or related dementia drug discovery proposal.
- 3) A one-page update on progress made in the previous funding period (if applicable).
- 4) NIH style biosketch (new style) listing all publications.
- 5) A statement declaring how you meet the eligibility criteria defined above.
- 6) Copies of UNMC transcripts
- 7) Letter of support from your mentor

Application Deadline is August 10th for a start date in August payroll

Funding: T32 funding is available for one year in the first instance with renewal possible based on progress and productivity. Up to eight scholarships are available for AY2027, **conditional on NIH funding award**.

T32 scholarships will provide:

- Stipend support at the NIH predoctoral level of \$29,364
- 60% of student fee costs up to a maximum of \$2,813.
- A travel budget of \$1,000 to support the student presenting their T32-funded research.
- Up to \$2,000 towards childcare costs.

Expectations: Trainees are expected to commit full time to the research training. Trainees must attend research seminars and symposia presented by the training program and any didactic courses as appropriate for their year of study. Trainees must fulfill all requirements of their respective degree program.

Trainees and mentors must acknowledge T32 support in all presentations and manuscripts resulting from the work of the trainee.

We encourage and welcome all qualified applicants to apply to the T32 training program.

For further information please contact the program directors: Dr. Paul Trippier (paul.trippier@unmc.edu) or Dr. Howard Fox (hfox@unmc.edu).